Developing and Activated T Cell Survival Depends on Differential Signaling Pathways to Regulate Anti-Apoptotic Bcl-xL by Wang, Ruiqing et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology




SignalingPathways to Regulate Anti-Apoptotic Bcl-xL
RuiqingWang,1,2 HuiminXie,3 Zhaofeng Huang,4 Weirong Shang,5 andZuoming Sun1
1Division of Immunology, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA
2Irell and Manella Graduate School of Biological Sciences, City of Hope, Duarte, CA 91010, USA
3Department of Microbiology and Immunology, Medical School of the University of Illinois, Chicago, IL 60612, USA
4Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, 510080, China
5Department of Gynecology and Obstetrics, Emory University School of Medicine, 550 Peachtree Street, Suite 1800, Atlanta,
GA 30308, USA
Correspondence should be addressed to Zuoming Sun, zsun@coh.org
Received 15 September 2011; Accepted 7 November 2011
Academic Editor: Ana Lepique
Copyright © 2012 Ruiqing Wang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Survival of T cells in both the central and peripheral immune system determines its ultimate function in the regulation of immune
responses. In the thymus, developing T cells undergo positive and negative selection to generate a T cell repertoire that responds
to foreign, but not self, antigens. During T cell development, the T cell receptor α chain is rearranged. However, the ﬁrst round
of rearrangement may fail, which triggers another round of α chain rearrangement until either successful positive selection or
cell death occurs. Thus, the lifespan of double positive (CD4+CD8+; DP) thymocytes determines how many rounds of α chain
rearrangement can be carried out and inﬂuences the likelihood of completing positive selection. The anti-apoptotic protein Bcl-
xL is the ultimate eﬀector regulating the survival of CD4+CD8+ thymocytes subject to the selection process, and the deletion
of Bcl-xL leads to premature apoptosis of thymocytes prior to the completion of the developmental process. In addition to its
critical function in the thymus, Bcl-xL also regulates the survival of peripheral T cells. Upon engagement with antigens, T cells
are activated and diﬀerentiated into eﬀectors. Activated T cells upregulate Bcl-xL to enhance their own survival. Bcl-xL-mediated
survival is required for the generation of eﬀectors that carry out the actual immune responses. In the absence of Bcl-xL,m a t u r eT
cells undergo apoptosis prior to the completion of the diﬀerentiation process to become eﬀector cells. Therefore, Bcl-xL ensures
the survival of both developing and peripheral T cells, which is essential for a functional immune system.
1.Introduction
Bcl-xL is an anti-apoptotic member of the Bcl-2 family of
apoptosis regulators. Proteins in this family contain at least
one of the four conserved α-helical motifs known as Bcl-
2 homology (BH) domains (BH1–BH4) [1]. The family
membersarefurtherclassiﬁedintothreesubgroups.Theﬁrst
group contains anti-apoptotic members that possess all four
BH domains and includes Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Bcl-B,
and A1. The other two groups are composed of proapoptotic
proteins, which are grouped into those containing three BH
domains, including Bax, Bak, and Bok; and those containing
BH3only,includingBad,Bid,Bim,Bmf,Bik,Hrk,Noxa,and
Puma. Anti-apoptotic Bcl-xL and Bcl-2 possess a hydropho-
bic cleft, the BH-3 binding groove, which can accommodate
BH3-only members of proapoptotic proteins and neutralize
their function [2, 3]. In T cells, Bcl-2 expression is relatively
consistent, whereas Bcl-xL expression is induced in response
to environment stimuli. In this paper, we will focus on the
functionandregulationofexpressionofBcl-xL indeveloping
and activated mature T cells.
2. Bcl-xL Function in the Development of
TCellsinthe Thymus
2.1. T Cell Development. Tc e l l sa r ec r i t i c a lc o m p o n e n t so f
adaptive immunity, as recognition of foreign antigens by T
cells initiates adaptive immune responses. The goal of T cell
development in thymus is to arm T cells with all necessary2 Clinical and Developmental Immunology
machineries to, upon activation in the periphery, launch
responses to foreign antigens by either direct killing (CD8+
T cells) or helping other immune cells battle the antigens
(CD4+ T cells). Therefore, during T cell development, T
cells must be educated to target only “nonself” foreign
antigens, and this is accomplished by eliminating self-
responsive T cells through positive and negative selection
in the thymus [4]. T cell development is usually divided
into three stages [5]: double negative (DN), double positive
(DP), and single positive (SP). At the DN stage, thymocytes
express neither CD4 nor CD8, and on the basis of their
expression of CD25 and CD44, they are further divided
into the DN1 (CD25−CD44+), DN2 (CD25+CD44+), DN3
(CD25+CD44−), and DN4 (CD25−CD44−) subsets. At the
DN3 stage, thymocytes start rearranging the T cell receptor
(TCR) β chain locus to produce the TCRβ chain, and only
those thymocytes that generate a successfully rearranged
TCRβ chain survive and progress in T cell development.
The successfully rearranged TCRβ chain, combined with the
invariant pre-TCRα chain, forms a pre-TCR, which delivers
signals to stimulate the proliferation of post-β thymocytes
and instruct the transition from the DN to DP stage. More
than 80% of all thymocytes are DP, and only about 5% are
positively selected and mature into either CD4+ or CD8+
SP cells if a DP thymocyte bears a TCR that interacts with
an MHC-self peptide complex with suﬃciently low aﬃnity.
The other DP T cells are negatively selected if the TCR is
recognized by an MHC-self peptide with high aﬃnity or die
by neglect if the TCR cannot be recognized at all [6]. Once
thymocytes mature into SP cells, they migrate out of the
thymus into peripheral lymphoid organs, such as the lymph
nodes and spleen, to mediate adaptive immunity.
2.2. Survival of DP Thymocytes Limits Positive Selection. A
critical event, α chain rearrangement, is carried out in DP
thymocytes. A productive α chain rearrangement generates
a TCR that recognizes self-MHC, and thus delivers survival
signals to allow the T cell to progress to the next stage.
However, if α chain rearrangement is not productive or
produces a TCR that does not recognize self-MHC, T cells
can initiate another round of α chain rearrangement. DP
thymocytes are able to initiate multiple rounds of TCRα
chain rearrangement until they are either positively selected
or die because they have reached the end of their lifespan.
Thus, the lifespan of DP thymocytes limits the progression
of TCRα chain rearrangement and controls the opportunity
for assembling a functional TCR [7]. The longer the lifespan
of DP cells, the more rounds of rearrangement they can try,
and therefore the greater the opportunity for the eventually
generation of a TCR that responds to foreign, but not self,
antigens. Given the importance of DP thymocyte survival, it
iscriticalthatthereareprecisemechanismsinplacetoensure
their survival.
2.3. Bcl-xL Is the Ultimate Survival Factor for DP Thymocytes.
The ﬁrst clue that Bcl-xL regulates DP thymocyte survival
was its unique expression pattern during T cell development
[8]. During the DN to DP transition, Bcl-xL is speciﬁcally
upregulated, whereas another survival factor Bcl-2 which
belongs to the same family as Bcl-xL, is downregulated. Fur-
thermore,Bcl-xL isdownregulatedwhileBcl-2isupregulated
in the following SP stage. The speciﬁc upregulation of Bcl-
xL during the DP stage strongly suggests that it functions
in DP thymocyte survival. Indeed, deletion of Bcl-xL led to
accelerated apoptosis of DP but not SP thymocytes both in
vitro and in vivo [8, 9], which corresponded to its expression
pattern in DP cells. In contrast, overexpression of Bcl-xL led
to a signiﬁcantly increased total thymocyte number due to
enhanced DP cell survival [10]. Bcl-xL, an anti-apoptotic
molecule, is therefore specially upregulated in DP thymo-
cytes to ensure their survival. This then raised the question
of what signals are required to stimulate Bcl-xL expression
in DP cells. Both our work as well as that of others has
demonstrated a network of transcriptional factors involved
in the regulation of Bcl-xL expression in DP thymocytes. We
will discuss each of these factors in the following sections.
2.4. RORγt. RORγt is a transcription factor that belongs to
the steroid nuclear receptor superfamily and was initially
identiﬁed by expression cloning to screen for molecules that
regulate activation-induced cell death [11]. We identiﬁed
RORγt by yeast two hybrid screening for CD4 interacting
proteins. However, CD4 only binds to RORγt in yeast,
and not in mammalian cells. Similar to Bcl-xL,R O R γti s
speciﬁcally upregulated in DP thymocytes during T cell
development, whereas its expression levels are extremely low
to undetectable in DN and SP cells. We created RORγt
knockout mice and demonstrated that RORγti sr e q u i r e d
for DP thymocyte survival and lymph-node genesis [12],
which was conﬁrmed by an independently generated RORγt
knockout mouse strain [13]. RORγt−/− mice have very small
thymuses due to apoptosis of DP thymocytes. The acceler-
ated DP apoptosis was accompanied by greatly reduced Bcl-
xL levels, and overexpression of Bcl-xL rescued RORγt−/−
thymocyte apoptosis, demonstrating that RORγte n h a n c e s
DP cell survival by upregulating Bcl-xL expression [12]. We
further demonstrated that recruitment of steroid receptor
coactivator (SRC) through the activation function 2 (AF2)
motif of RORγt is essential for supporting thymocyte
survival by RORγt[ 5, 14]. Thus, Bcl-xL was identiﬁed as a
downstream eﬀector of RORγt involved in regulation of DP
cell survival.
Our recent study also identiﬁed TCF-1 as the upstream
signaling molecule that regulates the RORγt-Bcl-xL pathway
in DP thymocytes.
2.5. TCF-1. TCF-1 is the ultimate eﬀector in the canonical
Wnt/β-catenin pathway. The Wnt-β-catenin pathway has
been shown to regulate multiple developmental processes,
ranging from regeneration of stem cells to organogenesis
of the kidney and reproductive systems [15]. β-catenin
is usually regulated at the protein level. In the absence
of Wnt signaling, several serines and threonines located
at the N-terminus of β-catenin (amino acids 31–45) are
phosphorylated by glycogen synthase-3β (GSK-3β)b o u n d
to the scaﬀolding proteins axin and adenomatous polyposisClinical and Developmental Immunology 3
coli (APC). The phosphorylated β-catenin is a target for
ubiquitination and degradation by the 26S proteasome [16].
In addition, there are reports that β-catenin can also be
degraded in a phosphorylation-independent manner [17,
18].Intheabsenceofβ-catenin,TCF-1isboundbycorepres-
sors such as Groucho/Transducin-like enhancer (GRG/TLE)
and turns oﬀ target gene expression. Activation of Wnt
signaling leads to inactivation of GSK-3β and accumulation
of nonphosphorylated β-catenin in the cytoplasm. Accumu-
lated β-catenin is then available to bind to and activate TCF-
1, which turns on target gene expression.
TCF-1 is important at multiple stages of thymocyte
development, including the DP stage. DP thymocytes from
TCF-1−/− mice undergo rapid apoptosis during in vitro
culture, and thymocyte survival can be restored by expres-
sion of full-length TCF-1 but not by truncated TCF-1 that
lacks the domain mediating the interaction with β-catenin,
suggesting that Wnt signaling mediated by β-catenin is
required to support DP thymocyte survival [19]. To further
establish the importance Wnt signaling in DP thymocyte
survival, we established a β-catenin transgenic mouse strain
(β-catTg) that overexpresses constitutively active β-catenin
under the control of a CD4 promoter [20]. The β-catenin
transgene is not expressed until the DP stage, which ensures
that thymocyte development at DN or earlier stages is not
aﬀected. As expected, the four DN subsets have normal
distribution and cell numbers in these mice. However, the
frequency and numbers of DP thymocytes are signiﬁcantly
greater in β-catTg mice than in wildtype (WT). In addition,
DP thymocytes from β-catTg mice undergo much slower
apoptosis than those of WT mice during both sponta-
neous and glucocorticoid-induced apoptosis. Furthermore,
promotion of DP thymocyte survival by the β-catenin
transgene is mediated by upregulation of Bcl-xL. These data
demonstrated that β-catenin/TCF-1 extends DP thymocyte
survival by up-regulating Bcl-xL. However, there was still the
question of whether Wnt signaling mediated by β-catenin/
TCF-1 directly targets Bcl-xL or acts through other fac-
tors.
Our recent work has shed light on this by showing that
enhancement of DP thymocyte survival by β-catenin/TCF-
1 is mediated by RORγt. Microarray analysis revealed
that RORγt was signiﬁcantly downregulated in TCF-1−/−
thymocytes that underwent accelerated apoptosis, whereas it
was greatly up-regulated in thymocytes that had enhanced
survival due to transgenic expression of β- catTg.B o t hTCF-
1−/− and RORγt−/− DP thymocytes underwent similar accel-
erated apoptosis. Forced expression of RORγt successfully
rescued TCF-1−/− DP thymocytes from apoptosis, whereas
ectopically expressed TCF-1 did not rescue the defective T
cell development due to lack of RORγt-supported survival.
Furthermore, activation of TCF-1 by stabilized β-catenin
could enhance DP thymocyte survival only in the presence
of RORγt, indicating that RORγt acts downstream of TCF-
1 during regulation of DP thymocyte survival. Moreover, β-
catenin/TCF-1 directly interacted with the RORγtp r o m o t e r
region and stimulated its activity. Thus, we showed that
TCF-1 enhances DP thymocyte survival through transcrip-
tional upregulation of RORγt, an essential survival molecule
for DP thymocytes that acts through upregulation of Bcl-xL
[9, 14].
2.6. c-Myb. A recent paper by Yuan et al. identiﬁed another
transcription factor, c-Myb, encoded by the proto-oncogene
Myb, as an important factor for regulating DP thymocyte
survival [21]. In this work, c-Myb was conditionally deleted
starting at the DP stage. This deletion led to premature
DP thymocyte apoptosis caused by decreased expression of
Bcl-xL .Morespeciﬁcally,duetoanenhanceddependenceon
Bcl-xL forsurvival,smallpreselectionDPthymocytesunder-
went faster premature apoptosis than large preselection and
postselection DP thymocytes. Forced expression of Bcl-xL
rescued thymocyte survival, and re-introduction of c-Myb
restored both Bcl-xL expression and the small preselection
DP compartment. The defective DP thymocyte survival
caused by reduced expression of Bcl-xL was reminiscent
of what has been observed in TCF-1−/− and RORγt
−/−
mice.However,theauthorsproposedthatthetranscriptional
regulation of Bcl-xL by c-Myb is independent of both TCF-
1a n dR O R γt, since c-Myb expression in both TCF-1- and
RORγt-deﬁcient thymocytes was comparable to that in WT
thymocytes, indicating that multiple pro-survival pathways
could synergize to ensure proper survival of DP thymocytes
via the Bcl-xL pathway.
2.7. HEB. HEB is a member of the E protein family. Thy-
mocytes from T lineage-speciﬁc HEB-deleted mice undergo
rapid apoptosis and have reduced Bcl-xL expression. In c-
Myb or RORγt-deﬁcient thymocytes, forced expression of
Bcl-xL rescued DP thymocyte survival, indicating that HEB
is another transcription factor that functions upstream of
Bcl-xL to promote DP thymocyte survival. In contrast to
the independence of RORγt and TCF-1 in c-Myb-mediated
regulation of DP thymocyte survival, HEB regulates RORγt
expression by binding to the two E-box sites present in the
RORγt promoter and stimulating its transcription, which
suggests that HEB could act upstream of RORγt in the same
pathwaytopromoteDPthymocytesurvival.SincebothTCF-
1 and HEB are upstream of RORγt, the relationship between
them during the regulation of DP cell survival remains to be
determined.
In summary, the transcription factors discussed above
work together to form a network for regulating DP thymo-
cyte survival through upregulation of Bcl-xL. This compli-
cated network ensures DP thymocytes complete their devel-
opment in the thymus to generate a functional immune
system that responds only to foreign antigens.
3. Bcl-xL FunctionduringActivationof
Peripheral Mature T Cells
3.1. T Cell Activation. Adaptive immunity is unique in that
only antigen-speciﬁc cells are activated to mediate immune
responses against speciﬁc pathogens. T cells that have
just migrated out of the thymus cannot mediate immune
responses and therefore are called na¨ ıve T cells. Eﬀector
Tc e l l sd i ﬀerentiated from na¨ ıve T cells mediate immune4 Clinical and Developmental Immunology
responses in vivo. Engagement of TCR by antigen initiates
TCR signals that trigger the activation and diﬀerentiation
of na¨ ıve T cells into eﬀector cells, which is an important
mechanism for ensuring that only antigen-speciﬁc T cells
are activated and clonally expanded to become competent
eﬀector cells. The T cell activation process is, therefore, not
only preparatory to arm T cells for attacking pathogens, but
also essential to ensure the adaptive nature of the immune
system.
3.2.SurvivalofActivatedTCellsDeterminesImmuneRespons-
es. An eﬃcient adaptive immune system must be able to
rapidlyexpandaswellasreducethenumberofimmunecells.
T cells meet these requirements, because they can be induced
toward proliferation, anergy, or apoptosis depending on the
signals received via the TCR. Na¨ ıve T cells are activated
to proliferate in response to foreign antigens, which is a
critical step in adaptive immunity. On the other hand, T
cells will undergo apoptosis or anergy if they engage with
self-antigens, which is an important mechanism for self-
tolerance. Productive engagement of the TCR results in
delivery of signals required for T cell proliferation as well
as T cell survival. If TCR-mediated survival signals are
blocked, T cells undergo apoptosis instead of proliferation
upon TCR stimulation. Therefore, TCR-delivered survival
signals ensure the completion of the T cell activation process
required for diﬀerentiation of na¨ ıve T cells into eﬀector cells
that mediate actual immune responses in vivo.
3.3. Bcl-xL E n h a n c e st h eS u r v i v a lo fA c t i v a t e dTC e l l s .Stim-
ulation of the TCR leads to T cell activation, resulting in
cell proliferation and production of IL-2. Proliferating T
cells, especially during S phase, are susceptible to apoptosis
[22,23].Thus,T CRsdeli v ersignalst oenhanc eTc ellsurvi val
during activation [24, 25]. Such survival signals include IL-2,
which acts as an extrinsic survival factor. More importantly,
activated T cells substantially up-regulate Bcl-xL,w h i c h
intrinsically increases their ability to resist apoptosis [23, 26,
27]. Without Bcl-xL, stimulation of T cells via the TCR leads
to apoptosis instead of clonal expansion. Therefore, Bcl-xL
ensures na¨ ıve T cells complete activation. This raises the
question of what TCR signals stimulate the upregulation of
Bcl-xL during T cell activation.
3.4.CD28. CD28,togetherwithitsligandsB7.1andB7.2,isa
costimulatorymoleculethattransducesthesecondarysignals
required for T cell activation. CD28 signaling markedly
lowerstheTCRsignalthresholdrequiredforTcellactivation,
and enhances cytokine production [28]. Another way CD28
facilitates T cell activation is by enhancing intrinsic T cell
survival [23, 27, 29]. CD28 costimulation augments the
expression of anti-apoptotic Bcl-xL, but not that of Bcl-2, to
render T cells resistant to apoptosis induced by crosslinking
of TCR and Fas, and withdrawal of IL-12 [30]. In contrast
to WT T cells, survival of T cells obtained from Bcl-xL
transgenic mice is not inhibited by blocking CD28 signals,
suggesting that CD28 costimulation sustains T cell survival
[29] and that downstream signaling molecules of CD28 are
also important for mediating the upregulation of Bcl-xL.
3.5. PI-3 Kinase. Distinct motifs within the cytoplasmic
domain of CD28 regulate T cell proliferation and induction
of Bcl-xL [31], suggesting diﬀerential signals are responsible
for these two CD28-regulated biological eﬀects. PI-3 kinase
is required for CD28-mediated induction of Bcl-xL,a s
upregulation of Bcl-xL is prevented by a pharmacological
inhibitor of PI-3 kinase and by mutation of the CD28
residues essential for PI-3 kinase activation [31, 32]. Further
evidence supporting a role of PI3-kinase in enhancement
of T cell survival is that Akt, a target of PI-3 kinase, has
been shown to mediate T cell survival by regulating Bcl-xL
[33]. Therefore, the PI-3 kinase-Akt pathway mediates CD28
signals to up-regulate Bcl-xL and enhance the survival of
activated T cells.
3.6. PKC-θ. CD28 also facilitates the activation of another
important signaling molecule, PKC-θ.P K C - θ mediates TCR
signals essential for T cell activation [34–36] and is required
to enhance the survival of activated CD4+ T cells by up-
regulating Bcl-xL. In response to TCR stimulation, CD4+
PKC-θ−/− T cells failed to up-regulate Bcl-xL and underwent
accelerated apoptosis via a caspase and mitochondria-
dependent pathway. Similar to these ﬁndings, siRNA-
mediated knockdown of PKC-θ in Jurkat cells also resulted
in apoptosis upon TCR stimulation. Forced expression of
Bcl-xL was suﬃcient to inhibit the apoptosis observed in
PKC-θ knockdown cells. Furthermore, ectopic expression of
PKC-θ stimulated a reporter gene driven by a mouse Bcl-
xL promoter, whereas the expression of an inactive form of
PKC-θ orknockdownofendogenousPKC-θ ledtoinhibition
of the Bcl-xL reporter. Thus, PKC-θ-mediated signals may
function not only in the initial activation of na¨ ıve CD4+
T cells, but also in their survival during T cell activation
by directly regulating Bcl-xL.P K C - θ has a similar function
in survival of CD8+ T cells [37]. We further demonstrated
thatPKC-θ-regulatedsurvivalisessentialforcardiacallograft
rejection in an adoptive transfer model [38], suggesting that
PKC-θ-mediated survival plays a role in immune responses
in vivo.
3.7. NF-κB. One of the critical downstream targets of PKC-
θ is NF-κB. We demonstrated that TCR-initiated NF-κB
activation was lacking in PKC-θ−/− Tl y m p h o c y t e s ,w h e r e a s
the activation of NF-κB by tumor-necrosis factor alpha and
interleukin-1 was not aﬀected in the absence of PKC-θ [36].
Similarly, PKC-θ wasalsofoundtomediateNF-κBacti vation
in Jurkat cells [39]. There is considerable evidence that
TCR-mediated activation of NF-κB extends T cell survival
[32, 40], raising the question of whether NF-κBi si m p o r t a n t
for Bcl-xL upregulation. Interestingly, functional NF-κB
binding sites are present on the promoter region of Bcl-xL
gene [41, 42]. We showed that PKC-θ-mediated activation of
Bcl-xL promoter was inhibited by dominant negative IKKβ,
suggesting that PKC-θ mediates the signals stimulating the
expression of Bcl-xL via the NF-κBp a t h w a y .S t i m u l a t i o no fClinical and Developmental Immunology 5
the PI-3 kinase/Atk pathway, which enhances T cell survival
in a similar manner as PKC-θ, leads to activation of NF-κB
[40], suggesting that the two pathways may interact in some
way during activation of NF-κB .A k ta c t i v a t i o ni sn o r m a l
in PKC-θ−/− T cells [43, 44], which suggests that Akt is not
downstream of PKC-θ during activation of NF-κB. There is
also no evidence to support that PKC-θ is downstream of
Akt. Therefore, the current model is that PKC-θ and Akt
cooperate with each other to mediate the CD28 signals and
activate NF-κB, which in turn, stimulates the expression of
Bcl-xL required to enhance the survival of activated T cells.
4. Summary
Bcl-xL is speciﬁcally up-regulated in DP thymocytes dur-
ing T cell development and in stimulated T cells during
T cell activation. This upregulation is important for the
completion of T cell development in the thymus as well as
the diﬀerentiation of na¨ ıve T cells into eﬀector cells in the
periphery.However,thesignalingpathwaysthatregulateBcl-
xL upregulationinthethymusandmatureTcellsaredistinct.
In the thymus, a transcription factor network that includes
TCF-1, RORγt, Heb, and c-Myb, which are also important
for T cell development, ensures DP thymocyte survival
by up-regulating Bcl-xL. Whereas in the periphery, CD28-
mediated activation of NF-κB via PKC-θ and Akt stimulates
Bcl-xL expression. Thus, developing and mature T cells use
thesamefactor,Bcl-xL,toenhancetheirsurvivalbutthrough
diﬀerent upstream signaling pathways. Expression of Bcl-xL,
in contrast to Bcl-2, is inducible and therefore modulates T
cellsurvivalinresponsetoenvironmentalsignals,whichisan
essential mechanism for maintaining a functional immune
system.
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